Core Laboratories (CLB) Cash & Equivalents (2022 - 2026)

Core Laboratories has reported Cash & Equivalents for 5 years, with the latest figure at $22.8 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 3.22% year-over-year to $22.8 million; the trailing twelve-month figure through Mar 2026 stood at $22.8 million (up 3.22% YoY), and the FY2025 full-year result was $22.7 million, up 18.5% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $22.8 million, up from $22.7 million in the prior quarter.
• The five-year high for Cash & Equivalents was $31.2 million in Q2 2025, with the low at $14.9 million in Q1 2024.
• Historically, Cash & Equivalents has averaged $20.9 million across 5 years, with a median of $21.5 million in 2024.
• Annual changes were most pronounced in 2024 — Cash & Equivalents tumbled 32.47% — and 2025, when it jumped 76.25%.
• Core Laboratories' Cash & Equivalents stood at $15.4 million in 2022, then retreated by 2.0% to $15.1 million in 2023, then climbed by 26.7% to $19.2 million in 2024, then advanced by 18.5% to $22.7 million in 2025, then climbed by 0.52% to $22.8 million in 2026.
• The last three Cash & Equivalents figures came in at $22.8 million (Q1 2026), $22.7 million (Q4 2025), and $25.6 million (Q3 2025), per Business Quant data.